{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:05:32Z","timestamp":1790399132720,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009371","name":"Universit\u00e9 de Nantes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009371","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jtct.2022.07.004","type":"journal-article","created":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T18:02:54Z","timestamp":1657476174000},"page":"679.e1-679.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["High Response Rate and Corticosteroid Sparing with Arsenic Trioxide-Based First-Line Therapy in Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"28","author":[{"given":"Dominique","family":"Rongvaux-Ga\u00efda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebva","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Poupon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouzha","family":"Djebrani-Oussedik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8777-2147","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.07.004_bib0001","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0002","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/asheducation-2008.1.134","article-title":"Recognizing and managing chronic graft-versus-host disease","author":"Lee","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2022.07.004_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.578314","article-title":"New approaches for the treatment of chronic graft-versus-host disease: current status and future directions","volume":"11","author":"Saidu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2022.07.004_bib0004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease","volume":"9","author":"Lee","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0005","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2015-05-640672","article-title":"Syk and tired of current chronic GVHD therapies","volume":"125","author":"Fowler","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.004_bib0006","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.21873\/anticanres.11483","article-title":"Acute graft-versus-host disease: a comprehensive review","volume":"37","author":"Nassereddine","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtct.2022.07.004_bib0007","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/bloodadvances.2017013052","article-title":"Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants","volume":"2","author":"Kumar","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.07.004_bib0008","first-page":"975","article-title":"Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Cheon","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtct.2022.07.004_bib0009","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2012.09128.x","article-title":"Diagnosis and management of chronic graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.07.004_bib0011","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.004_bib0012","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1182\/blood-2006-04-020610","article-title":"Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL\/lpr mice","volume":"108","author":"Bob\u00e9","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.004_bib0013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1753425910371668","article-title":"Arsenic trioxide reduces 2,4,6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-\u03baB down-regulation and caspase-3 activation","volume":"17","author":"Singer","year":"2011","journal-title":"Innate Immun"},{"key":"10.1016\/j.jtct.2022.07.004_bib0014","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1002\/art.34534","article-title":"Reactive oxygen species-mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis","volume":"64","author":"Kavian","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jtct.2022.07.004_bib0015","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.4049\/jimmunol.1103538","article-title":"Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease","volume":"188","author":"Kavian","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2022.07.004_bib0016","doi-asserted-by":"crossref","first-page":"608","DOI":"10.5500\/wjt.v6.i4.608","article-title":"Biology of chronic graft-vs-host disease: immune mechanisms and progress in biomarker discovery","volume":"6","author":"Presland","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0017","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1007\/s11427-019-1691-x","article-title":"Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.jtct.2022.07.004_bib0018","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/347558a0","article-title":"The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus","volume":"347","author":"de Th\u00e9","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2022.07.004_bib0019","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12185-015-1782-4","article-title":"Therapeutic benefits targeting B-cells in chronic graft-versus-host disease","volume":"101","author":"Nakasone","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.07.004_bib0020","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.bbmt.2020.07.026","article-title":"Single-agent cyclosporine for graft-versus-host disease prophylaxis in patients with acquired aplastic anemia receiving fludarabine-based conditioning","volume":"26","author":"Iftikhar","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0021","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0022","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","article-title":"Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale","volume":"19","author":"McQuellon","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0023","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0024","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2011.254","article-title":"Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity","volume":"26","author":"Grkovic","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.07.004_bib0025","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.bbmt.2014.06.040","article-title":"A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease","volume":"20","author":"Herrera","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.jtct.2022.07.004_bib0026","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41409-018-0134-4","article-title":"Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD","volume":"53","author":"Jain","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0027","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620717741860","article-title":"New and emerging therapies for acute and chronic graft versus host disease","volume":"9","author":"Hill","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtct.2022.07.004_bib0028","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41409-018-0399-7","article-title":"Safety and efficacy of rituximab-based first line treatment of chronic GVHD","volume":"54","author":"Solomon","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0029","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2017-05-786137","article-title":"Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study","volume":"130","author":"Malard","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.004_bib0030","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.bbmt.2015.03.014","article-title":"Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results","volume":"21","author":"Pidala","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0031","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease","volume":"7","author":"Arora","year":"2001","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.jtct.2022.07.004_bib0032","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2011.05.016","article-title":"Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study","volume":"18","author":"Gilman","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.004_bib0033","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V96.12.3995","article-title":"Thalidomide for treatment of patients with chronic graft-versus-host disease","volume":"96","author":"Koc","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.004_bib0034","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.004_bib0035","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/2040620713490316","article-title":"Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion","volume":"4","author":"Hart","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtct.2022.07.004_bib0036","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/bloodadvances.2019000145","article-title":"Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD","volume":"3","author":"Jagasia","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.07.004_bib0037","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.V100.1.48","article-title":"Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone","volume":"100","author":"Koc","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.004_bib0038","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","article-title":"Current issues in chronic graft-versus-host disease","volume":"124","author":"Soci\u00e9","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.004_bib0039","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2008-03-141481","article-title":"A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease","volume":"112","author":"Flowers","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.004_bib0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1476-069X-12-73","article-title":"Arsenic immunotoxicity: a review","volume":"12","author":"Dangleben","year":"2013","journal-title":"Environ Health"},{"key":"10.1016\/j.jtct.2022.07.004_bib0041","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/xen.12238","article-title":"As2 O3 combined with leflunomide prolongs heart xenograft survival via suppressing the response of Th1, Th2, and B cells in a rat model","volume":"23","author":"Jiao","year":"2016","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.jtct.2022.07.004_bib0042","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1021\/cr300015c","article-title":"Arsenic binding to proteins","volume":"113","author":"Shen","year":"2013","journal-title":"Chem Rev"},{"key":"10.1016\/j.jtct.2022.07.004_bib0043","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.004_bib0044","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.07.004_bib0045","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2003.01.149","article-title":"Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia","volume":"21","author":"Raffoux","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.004_bib0046","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3324\/haematol.2019.229583","article-title":"Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders","volume":"105","author":"Ravandi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.07.004_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115299","article-title":"Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia","volume":"409","author":"Wang","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jtct.2022.07.004_bib0048","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-021-02454-6","article-title":"Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)","volume":"23","author":"Hamidou","year":"2021","journal-title":"Arthritis Res Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722014695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722014695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:05:13Z","timestamp":1763003113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722014695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2666636722014695"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.07.004","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Response Rate and Corticosteroid Sparing with Arsenic Trioxide-Based First-Line Therapy in Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}